Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:8923
Name skin melanoma
Definition A skin cancer that has_material_basis_in melanocytes.
Source DiseaseOntology.org
Alt Ids DOID:10043 DOID:10051 DOID:0050609 DOID:10046 DOID:10052 DOID:10055 DOID:8922
Path disease disease of cellular proliferation cancer organ system cancer integumentary system cancer skin cancer skin melanoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF V600E Ganetespib skin melanoma sensitive detail...
BRAF V600K Dabrafenib skin melanoma sensitive detail...
BRAF V600X Dabrafenib skin melanoma sensitive detail...
BRAF V600X Vemurafenib skin melanoma sensitive detail...
KIT act mut Imatinib skin melanoma sensitive detail...
NRAS mutant Binimetinib skin melanoma sensitive detail...
BRAF V600K Vemurafenib skin melanoma sensitive detail...
BRAF V600E Dabrafenib skin melanoma sensitive detail...
BRAF V600E Vemurafenib skin melanoma sensitive detail...
BRAF V600E Dabrafenib + Trametinib skin melanoma sensitive detail...
BRAF V600E Cobimetinib + Vemurafenib skin melanoma sensitive detail...
BRAF V600E Binimetinib + Encorafenib skin melanoma sensitive detail...
BRAF V600E/K Vemurafenib skin melanoma sensitive detail...
BRAF V600E/K Binimetinib + Encorafenib skin melanoma sensitive detail...
BRAF V600K Cobimetinib + Vemurafenib skin melanoma sensitive detail...
BRAF V600K Dabrafenib + Trametinib skin melanoma sensitive detail...
BRAF V600K Binimetinib + Encorafenib skin melanoma sensitive detail...
BRAF V600X Cobimetinib + Vemurafenib skin melanoma sensitive detail...
BRAF V600X Dabrafenib + Trametinib skin melanoma sensitive detail...
BRAF V600X Binimetinib + Encorafenib skin melanoma sensitive detail...
BRAF V600E CDKN2A R80* Dabrafenib + Trametinib skin melanoma predicted - sensitive detail...
CDKN2A mutant N/A skin melanoma not applicable detail...
PTEN mutant N/A skin melanoma not applicable detail...
BRAF V600E Trametinib + YM-254890 skin melanoma no benefit detail...
BRAF V600E YM-254890 skin melanoma no benefit detail...
KIT act mut Dasatinib skin melanoma sensitive detail...
KIT act mut Nilotinib skin melanoma sensitive detail...
KIT act mut Ripretinib skin melanoma sensitive detail...
ROS1 fusion Crizotinib skin melanoma sensitive detail...
ROS1 fusion Entrectinib skin melanoma sensitive detail...
BRAF fusion Trametinib skin melanoma sensitive detail...
BRAF V600K Dabrafenib + Pembrolizumab + Trametinib skin melanoma sensitive detail...
BRAF V600E Dabrafenib + Pembrolizumab + Trametinib skin melanoma sensitive detail...
BRAF V600X Dabrafenib + Pembrolizumab + Trametinib skin melanoma sensitive detail...
BRAF V600X Atezolizumab + Cobimetinib + Vemurafenib skin melanoma sensitive detail...
BRAF V600E Atezolizumab + Cobimetinib + Vemurafenib skin melanoma sensitive detail...
BRAF V600K Atezolizumab + Cobimetinib + Vemurafenib skin melanoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01107665 Phase II Paclitaxel + Pazopanib Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma Completed USA 0
NCT01693068 Phase II Dacarbazine Pimasertib Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma Completed USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUS 4
NCT01989585 Phase Ib/II Dabrafenib + Navitoclax + Trametinib Dabrafenib + Trametinib Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma Active, not recruiting USA 0
NCT02203604 Phase II Aldesleukin + Ipilimumab High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery Terminated USA 0
NCT02346955 Phase I CM-24 CM-24 + Pembrolizumab Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) Terminated USA 1
NCT02535078 Phase Ib/II Durvalumab Tebentafusp Tremelimumab Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma Completed USA 0
NCT02581930 Phase II Ibrutinib Ibrutinib in Treating Patients With Refractory Stage IV Cutaneous Melanoma Active, not recruiting USA 0
NCT02645149 Phase II Trametinib Pazopanib Ceritinib Ribociclib + Trametinib Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (MatchMel) Recruiting AUS 0
NCT02680184 Phase I Pembrolizumab + Vidutolimod Clinical Study of CMP-001 in Combination With Pembrolizumab Completed USA 0
NCT02731729 Phase II Ipilimumab Nivolumab Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy Completed USA 0
NCT02748564 Phase II Aldesleukin + Pembrolizumab Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma Terminated USA 0
NCT02818023 Phase I Cobimetinib + Pembrolizumab + Vemurafenib Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma Terminated USA 0
NCT02829099 Phase I JNJ-64457107 A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors Completed ESP 1
NCT03084640 Phase Ib/II Pembrolizumab + Vidutolimod Phase 1b Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Subjects With Advanced Melanoma Completed USA 0
NCT03089606 Phase II Pembrolizumab Pembrolizumab TX-naive Distant Mets Melanoma and Use of AMT (PET) at Baseline as Imaging Biomarker Completed USA 0
NCT03235245 Phase II Binimetinib + Encorafenib Ipilimumab + Nivolumab Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (EBIN) Active, not recruiting NLD | ITA | GBR | FRA | ESP | DEU 3
NCT03278665 Phase Ib/II Domatinostat + Pembrolizumab 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy (SENSITIZE) Completed ITA | DEU 0
NCT03340129 Phase II Ipilimumab + Nivolumab Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) (ABC-X) Recruiting AUS 1
NCT03405155 Phase II Nivolumab Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery Active, not recruiting USA 0
NCT03551626 Phase III Dabrafenib + Trametinib Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes (COMBI-APlus) Completed ITA | GBR | FRA | CAN | AUS 18
NCT03553836 Phase III Pembrolizumab Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 7
NCT03618641 Phase II Nivolumab + Vidutolimod CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease Completed USA 0
NCT03693612 Phase Ib/II GSK3359609 + Tremelimumab Paclitaxel Docetaxel Cetuximab GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors Completed USA | CAN | AUS 0
NCT03733990 Phase Ib/II FP-1305 A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) Completed USA | NLD | GBR | FRA | ESP 1
NCT03754179 Phase Ib/II Dabrafenib + Hydroxychloroquine + Trametinib Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma (COMBI-R2) Unknown status BEL 0
NCT03817125 Phase I Nivolumab + SER-401 Vancomycin Nivolumab Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (MCGRAW) Completed USA 0
NCT03829254 Phase Ib/II NUC-7738 NUC-7738 + Pembrolizumab A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma Recruiting GBR 0
NCT03842943 Phase II Pembrolizumab + Talimogene laherparepvec Neoadjuvant Combination Immunotherapy for Stage III Melanoma Recruiting USA 0
NCT03864042 Phase I Caffeine + Dextromethorphan + Losartan + Midazolam + Omeprazole Modafinil Bupropion + Rosuvastatin Binimetinib + Encorafenib Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors Active, not recruiting USA | NLD | ESP | CAN | BEL 0
NCT03875079 Phase I Pembrolizumab + RO6874281 A Phase IB Study To Evaluate Safety And Therapeutic Activity Of RO6874281, An Immunocytokine, Consisting Of Interleukin-2 Variant Targeting Fibroblast Activation Protein-A, In Combination With Pembrolizumab (Anti-Pd-1), In Participants With Previously Untreated Advanced And/Or Metastatic Melanoma Completed USA | FRA | ESP | CAN | BEL | AUS 1
NCT03897881 Phase II mRNA-4157 + Pembrolizumab Pembrolizumab An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Patients With High-Risk Melanoma (KEYNOTE-942) Recruiting USA | AUS 0
NCT03898908 Phase II Binimetinib + Encorafenib Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain (EBRAIN-MEL) Active, not recruiting ESP 0
NCT03947385 Phase Ib/II IDE196 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions Recruiting USA | CAN | AUS 0
NCT03972046 Phase II Dabrafenib + Talimogene laherparepvec + Trametinib Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma Withdrawn USA 0
NCT03991741 Phase I Aldesleukin Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors Recruiting USA 0
NCT04007588 Phase II Ipilimumab + Nivolumab Nivolumab Linrodostat + Nivolumab A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma Withdrawn USA 0
NCT04020809 Phase I Atezolizumab Neoadjuvant Atezolizumab in Cutaneous Melanoma Recruiting USA 0
NCT04042480 Phase I SGN-CD228A A Study of SGN-CD228A in Advanced Solid Tumors Terminated USA | ITA | GBR | FRA | ESP 0
NCT04042506 Phase II Nivolumab SBRT as a Vaccination for Metastatic Melanoma Withdrawn USA 0
NCT04074096 Phase II Binimetinib + Encorafenib + Pembrolizumab Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis (BEPCOME-MB) Recruiting FRA 0
NCT04099251 Phase III Nivolumab Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma (CheckMate76K) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 9
NCT04130516 Phase Ib/II LNS8801 LNS8801 + Pembrolizumab Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab Recruiting USA 0
NCT04135352 Phase I Pembrolizumab + V938 A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001) Terminated USA | CAN 1
NCT04136834 Phase I Pegtomarginase A Phase I Open-label Study for Subjects With Advanced Malignancies (PT01) Unknown status USA 0
NCT04139902 Phase II Cobolimab + Dostarlimab-gxly Dostarlimab-gxly PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor TSR-022 and PD-1 Inhibitor Dostarlimab (TSR-042) Recruiting USA 0
NCT04207086 Phase II Lenvatinib + Pembrolizumab Pembrolizumab A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma (Neo PeLe) Active, not recruiting AUS 0
NCT04221438 Phase II Binimetinib + Encorafenib Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement Active, not recruiting USA 0
NCT04250597 Phase I GNX102 Study of GNX102 in Patients With Advanced Solid Tumors Terminated USA 1
NCT04261439 Phase I NIZ985 NIZ985 + Spartalizumab A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab Terminated USA | ITA | ESP | DEU | BEL 2
NCT04301011 Phase Ib/II TBio-6517 Pembrolizumab + TBio-6517 Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (RAPTOR) Terminated USA | CAN 1
NCT04338685 Phase I RO7119929 + Tocilizumab A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases Completed USA | ESP 4
NCT04356729 Phase II Atezolizumab + Bevacizumab A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma Recruiting USA 0
NCT04375527 Phase II Binimetinib + Nivolumab Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma Recruiting USA 0
NCT04381650 Phase Ib/II Pembrolizumab + Subasumstat A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors Active, not recruiting USA 8
NCT04401995 Phase II Nivolumab Nivolumab + Vidutolimod Study of TLR9 Agonist CMP-001 in Combination With Nivolumab vs. Nivolumab Active, not recruiting USA 0
NCT04410445 Phase III Nivolumab Nivolumab + NKTR-214 Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12) Terminated USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | AUT | AUS 7
NCT04455503 Phase Ib/II EVX-02 + Nivolumab Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 Terminated AUS 0
NCT04493203 Phase II Axitinib + Nivolumab Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma Active, not recruiting USA 0
NCT04495010 Phase II Nivolumab Ipilimumab + Nivolumab Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants (CheckMate 7UA) Withdrawn USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS 6
NCT04521413 Phase Ib/II CFI-402411 + Pembrolizumab CFI-402411 Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies Recruiting USA | CAN 1
NCT04526899 Phase II Cemiplimab BNT111 BNT111 + Cemiplimab Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD1-refractory/Relapsed, Unresectable Stage III or IV Melanoma Active, not recruiting USA | ITA | GBR | ESP | DEU | AUS 1
NCT04551352 Phase I RO7293583 + Tocilizumab Obinutuzumab + RO7293583 + Tocilizumab A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas Completed USA | ESP | CAN | BEL | AUS 1
NCT04570332 Phase II BO-112 + Pembrolizumab BO-112 With Pembrolizumab in Unresectable Malignant Melanoma (SPOTLIGHT203) Active, not recruiting FRA | ESP 0
NCT04577807 Phase II PVSRIPO + unspecified PD-1 antibody PVSRIPO PVSRIPO With or Without Immune Checkpoint Blockade in Patients With Advanced PD-1 Refractory Melanoma Active, not recruiting USA 0
NCT04592653 Phase Ib/II ALKS 4230 ALKS 4230 + Pembrolizumab Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3) Recruiting USA | ESP 0
NCT04609566 Phase II Brentuximab vedotin + Pembrolizumab Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors Recruiting USA | CAN 0
NCT04620603 Phase Ib/II Nivolumab Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer Recruiting USA 0
NCT04657991 Phase III Pembrolizumab Binimetinib + Encorafenib + Pembrolizumab A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma Active, not recruiting USA | NZL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT 17
NCT04697576 Phase I Nivolumab Pembrolizumab Ipilimumab Intralesional Influenza Vaccine for the Treatment of Stage I, II, and IV Melanoma Recruiting USA 0
NCT04703426 Phase II Pembrolizumab + Sargramostim Sargramostim (GM-CSF) + PD-1 Withdrawn 0
NCT04706962 Phase I TH1902 TH1902 in Patients With Advanced Solid Tumors Recruiting USA | CAN 0
NCT04759846 Phase I Binimetinib + Encorafenib Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma Withdrawn ITA | ESP 1
NCT04830124 Phase II ALKS 4230 Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6 (ARTISTRY-6) Recruiting USA | ITA | GBR | ESP | CAN | AUS 2
NCT04835805 Phase I Belvarafenib + Cobimetinib + Nivolumab Belvarafenib + Cobimetinib Belvarafenib A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma. Active, not recruiting USA | DEU | CAN | AUS 2
NCT04901988 Phase II Nivolumab Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION (DETECTION) Terminated GBR 0
NCT04930783 Phase I CDX-301 + Nivolumab + Poly ICLC NeoVax + CDX-301 and Nivolumab in Advanced Melanoma Recruiting USA 0
NCT04958239 Phase I BI 765179 + Ezabenlimab BI 765179 A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) Recruiting USA | NLD | ITA | ESP | BEL 1
NCT04995094 Phase II Pembrolizumab Pembrolizumab + PGG beta-glucan Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma Withdrawn USA 0
NCT05050006 Phase II ITIL-168 ITIL-168 in Advanced Melanoma (DELTA-1) Terminated USA | GBR | CAN 0
NCT05060003 Phase II Atezolizumab Atezolizumab + Tiragolumab Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection Terminated USA 0
NCT05061017 Phase II Cyclophosphamide + Nivolumab + PG545 Nivolumab + PG545 Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) Active, not recruiting USA 0
NCT05061134 Phase II Ceralasertib + Durvalumab Ceralasertib A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition (MONETTE) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 2
NCT05069935 Phase I Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors Terminated USA 0
NCT05086692 Phase Ib/II MDNA11 + Pembrolizumab A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) Recruiting USA | CAN | AUS 1
NCT05098210 Phase I NeoVax + Nivolumab + Poly ICLC Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer Recruiting USA 0
NCT05130177 Phase II AB154 + Zimberelimab Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma Recruiting USA 0
NCT05200143 Phase II Cabozantinib + Ipilimumab + Nivolumab Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma Active, not recruiting USA 0
NCT05200559 Phase Ib/II E7777 + Pembrolizumab T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors Recruiting USA 0
NCT05203172 FDA approved Encorafenib Binimetinib + Encorafenib Binimetinib + Encorafenib + Ribociclib Binimetinib + Cetuximab + Encorafenib Binimetinib The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS 8
NCT05270044 Phase III Binimetinib + Encorafenib Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (COLUMBUS-AD) Active, not recruiting NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 13
NCT05280314 Phase II IO102-IO103 + Pembrolizumab Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab in Patients With Resectable Tumors Recruiting USA | FRA | ESP | DEU | AUS 1
NCT05315258 Phase II Tebentafusp Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma (TebeMRD) Recruiting GBR 0
NCT05415072 Phase Ib/II DYP688 A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas Recruiting USA | NLD | FRA | ESP | DEU | AUS 1
NCT05418972 Phase II Nivolumab and relatlimab-rmbw A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma (Neo ReNi II) Recruiting AUS 0
NCT05479812 Phase I WTX-124 Pembrolizumab + WTX-124 Dose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT05482074 Phase II Olaparib Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 Withdrawn 0
NCT05492682 Phase I Cyclophosphamide + Pembrolizumab + PeptiCRAd-1 START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer Recruiting DEU 0
NCT05529316 Phase II Botensilimab A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma Suspended USA | ITA | GBR | FRA | ESP | DEU | BEL 3
NCT05533697 Phase Ib/II mRNA-4359 + Pembrolizumab mRNA-4359 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors Recruiting USA | GBR | ESP | AUS 0
NCT05544929 Phase I KFA115 KFA115 + Pembrolizumab A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers Recruiting USA | ITA | ESP | DEU | CAN 4
NCT05571839 Phase I SGN-BB228 A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors Recruiting USA | GBR | FRA | DEU | CAN 1
NCT05572463 Phase Ib/II IBI110 + Sintilimab A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma Withdrawn USA | GBR | FRA | ESP | DEU | AUS 1
NCT05576077 Phase I Pembrolizumab + TBio-4101 A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors (STARLING) Recruiting USA | CAN 0
NCT05578872 Phase Ib/II ANV419 + Ipilimumab ANV419 + Pembrolizumab ANV419 A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (ANV419-101). Recruiting USA | ITA | FRA | ESP | DEU 0
NCT05580770 Phase Ib/II BGB3245 + PD-0325901 Mirdametinib + BGB-3245 in Advanced Solid Tumors Recruiting USA | AUS 0
NCT05620914 Phase I Patritumab deruxtecan A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases (PARAMETer) Not yet recruiting USA 0
NCT05628883 Phase I Cyclophosphamide + Fludarabine TBio-4101 Aldesleukin Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma Recruiting USA 0
NCT05665595 Phase III Pembrolizumab MK-7684A A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) Active, not recruiting USA | NZL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 15
NCT05709821 Phase Ib/II Pembrolizumab IMM60 IMM60 + Pembrolizumab IMM60 and Pembrolizumab in Melanoma and NSCLC Terminated USA | GBR | ESP 0
NCT05764395 Phase II Pembrolizumab + Rigosertib Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors Recruiting USA 0
NCT05767879 Phase II Binimetinib + Encorafenib (Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma Recruiting NLD 0
NCT05836324 Phase I INCA33890 A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors Recruiting USA | ITA | GBR | FRA | ESP 2
NCT05841563 Phase I PM54 Clinical Trial of PM54 in Advanced Solid Tumors Patients. Recruiting USA | ESP | BEL 0
NCT05879822 Phase II INCB099280 A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive Recruiting NZL 9
NCT05909995 Phase I INCB099280 + Ipilimumab Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors Recruiting USA | CAN 2
NCT05926960 Phase II Binimetinib + Encorafenib + Pembrolizumab Ipilimumab + Nivolumab A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma (PORTSIDE) Recruiting ITA | GBR | ESP | DEU 3
NCT05933577 Phase III Pembrolizumab mRNA-4157 + Pembrolizumab A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001) Recruiting USA | NZL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 13
NCT06030037 Phase II Lenvatinib + Pembrolizumab Pembrolizumab/Lenvatinib With and Without Responder-derived FMT in Relapsed/Refractory Melanoma Not yet recruiting USA 0
NCT06099782 Phase II MK-3475A Pembrolizumab A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) Recruiting USA | NZL | FRA | AUS 6
NCT06171178 Phase I ASP1012 + Pembrolizumab ASP1012 A Study of ASP1012 in Adults With Solid Tumors Recruiting USA 0
NCT06194929 Phase Ib/II Defactinib + Encorafenib + RO5126766 Defactinib + RO5126766 Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma (DETERMINE) Recruiting USA 0
NCT06240143 Phase Ib/II Ipilimumab + Nivolumab Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma (MARIANE) Not yet recruiting NLD 0
NCT06250335 Phase II Ipilimumab + Nivolumab Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients Recruiting USA 0
NCT06331598 Phase II Atezolizumab Atezolizumab + Tiragolumab A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) (IMperator) Recruiting ESP 0
NCT06346067 Phase III LXH 254 + Trametinib Trametinib Dacarbazine Temozolomide A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) Recruiting USA 0